"Liquid Biopsies Predict Treatment Response and Survival in Gynecologic Cancers"
A new study has demonstrated for the first time that personalized circulating tumor DNA (ctDNA) biomarkers in gynecologic cancers can detect the presence of residual tumor earlier than currently used serum and imaging studies. “Detection of residual disease represents a diagnostic dilemma and potential critical inflection point in precision medicine,” said John A. Martignetti, MD, PhD, an associate professor of oncological sciences at the Icahn School of Medicine at Mount Sinai. Learn more.